Search

Search Constraints

You searched for: Author/Creator Cavenagh, Jamie

Search Results

1. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. (4th December 2012)

2. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial. (20th April 2015)

3. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. Issue 12 (December 2016)

4. British Committee for Standards in Haematology guidelines for aplastic anemia: Single centre retrospective review finds no compelling evidence for the recommended higher platelet count threshold of 20 × 109/L ‐ RESPONSE to Yan et al. (23rd May 2017)

5. Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open‐label, phase 1/2 study. (31st March 2019)

6. Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial). (20th August 2018)

7. GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML. Issue 11 (November 2018)

8. Guidelines for the diagnosis and management of adult aplastic anaemia. (16th November 2015)